PBMCs from HLA-A24+ prostate cancer patients showed peptide-specific IFN-γ production in six or seven of 10 patients when stimulated with the PTHrP102–110 and PTHrP36–44 peptide, respectively. This evidence concerns the gene IFNG and prostate cancer.